1246852-76-5

Upstream product

• 1459-96-7 dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate 
• 23062-52-4 methyl 4-phenylbicyclo<2.2.2>octane-1-carboxylate 
• 23062-51-3 methyl 4-bromo-bicyclo[2.2.2]octane-1-carboxylate 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 593-71-5 Chloroiodomethane 
• 1246852-75-4 methyl 4-(4-bromophenyl)bicyclo[2.2.2]octane-1-carboxylate 

Downstream Products

• 1246852-78-7 C₂₆H₃₅BrN₂O₄ 
• 1246852-77-6 2-amino-1-(4-(4-bromophenyl)bicyclo[2.2.2]octan-1-yl)ethanone hydrochloride 

Relevant academic research and scientific papers

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.